DK1589987T3 - Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår - Google Patents

Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår

Info

Publication number
DK1589987T3
DK1589987T3 DK04705973.8T DK04705973T DK1589987T3 DK 1589987 T3 DK1589987 T3 DK 1589987T3 DK 04705973 T DK04705973 T DK 04705973T DK 1589987 T3 DK1589987 T3 DK 1589987T3
Authority
DK
Denmark
Prior art keywords
cathelicidin
treatment
peptide derivatives
scars
chronic
Prior art date
Application number
DK04705973.8T
Other languages
English (en)
Inventor
Hle-Bäckdahl Mona St
Johan Heilborn
Conny Bogentoft
Anders Carlsson
Original Assignee
Lipopeptide Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20290232&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1589987(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipopeptide Ab filed Critical Lipopeptide Ab
Application granted granted Critical
Publication of DK1589987T3 publication Critical patent/DK1589987T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
DK04705973.8T 2003-01-29 2004-01-28 Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår DK1589987T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition
US44496403P 2003-02-05 2003-02-05
PCT/SE2004/000111 WO2004067025A1 (en) 2003-01-29 2004-01-28 Use of the cathelicidin ll-37 and derivatives thereof for wound healing

Publications (1)

Publication Number Publication Date
DK1589987T3 true DK1589987T3 (da) 2014-05-26

Family

ID=20290232

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04705973.8T DK1589987T3 (da) 2003-01-29 2004-01-28 Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår

Country Status (14)

Country Link
US (5) US7452864B2 (da)
EP (1) EP1589987B1 (da)
JP (1) JP4750690B2 (da)
CN (3) CN105079784B (da)
CA (1) CA2513598C (da)
CY (1) CY1115142T1 (da)
DK (1) DK1589987T3 (da)
ES (1) ES2467090T3 (da)
HK (1) HK1217661A1 (da)
PT (1) PT1589987E (da)
SE (1) SE0300207D0 (da)
SI (1) SI1589987T1 (da)
WO (1) WO2004067025A1 (da)
ZA (1) ZA200505830B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7777000B2 (en) * 2003-03-06 2010-08-17 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides
EP1660632B1 (en) 2003-08-01 2014-02-19 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
CA2535029C (en) 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US7776823B2 (en) * 2003-10-21 2010-08-17 The Regents Of The University Of California Human cathelicidin antimicrobial peptides
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
CN101142233A (zh) * 2004-12-22 2008-03-12 利波佩普蒂德有限公司 抑制cathelin样蛋白hCAP18/LL-17的试剂
JP5846711B2 (ja) * 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2452691A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention of diabetic and aged skin
AU2007262776A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hCAP18 ) as anticancer agent
WO2008073174A2 (en) * 2006-09-08 2008-06-19 The Regents Of The University Of California Antimicrobial therapy
WO2008060362A2 (en) * 2006-09-27 2008-05-22 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
WO2008103751A2 (en) * 2007-02-20 2008-08-28 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
CA2691645A1 (en) * 2007-06-25 2008-12-31 Lipopeptide Ab New medical products
CA2696833A1 (en) * 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
AU2008281374B2 (en) * 2007-07-30 2012-05-31 Healor Ltd. Pharmaceutical composition for treating wounds and related methods
WO2010139195A1 (en) * 2009-06-04 2010-12-09 The Chinese University Of Hong Kong Anti-inflammatory bacteria
EP4089169A1 (en) 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
JP2013510085A (ja) * 2009-11-03 2013-03-21 リピドール エービー 創傷治療促進用組成物
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2012150890A1 (en) * 2011-05-02 2012-11-08 Lipidor Ab Antibacterial composition
KR20140136494A (ko) * 2012-03-20 2014-11-28 헬릭스 바이오메딕스, 인코포레이티드 짧은 항균 지질펩티드
WO2014004719A2 (en) 2012-06-26 2014-01-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
EP2821077A1 (en) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
CN103920137B (zh) * 2014-04-28 2016-03-30 中国药科大学 一种具有抗耐药性革兰阳性细菌作用的药物组合物
US10138282B2 (en) * 2014-05-27 2018-11-27 Indiana University Research And Technology Corporation Peptide antagonist of LL-37
CN104984321A (zh) * 2015-07-24 2015-10-21 中国药科大学 人源抗菌肽ll-37在制备治疗或预防血栓性疾病药物中的应用
CN105859867A (zh) * 2016-05-30 2016-08-17 黄石市中心医院 一种人源抗菌肽ll-37突变体及其应用
CN106519042A (zh) * 2016-12-29 2017-03-22 陕西慧康生物科技有限责任公司 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因
US20190300575A1 (en) 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same
CN108659102B (zh) * 2018-04-25 2021-08-17 南方医科大学 具有抗菌及抗炎活性的多肽化合物
ES2799098B2 (es) 2019-06-10 2021-12-10 Univ Madrid Carlos Iii Aptameros agonistas del receptor fpr2 y usos de los mismos
KR102475936B1 (ko) * 2020-10-15 2022-12-09 코스맥스 주식회사 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
CA2182576C (en) 1994-02-04 2002-09-17 Anders Carlsson Bilayer preparations
ATE201981T1 (de) 1994-02-04 2001-06-15 Scotia Lipidteknik Ab Öl-in-wasser-emulsionen
JP3203359B2 (ja) 1994-02-04 2001-08-27 リポコーア・ホールディング・アクチエボラーグ 親油性担体製剤
SE9403055L (sv) 1994-09-13 1996-03-14 Hans G Boman Nytt humant peptidantibiotikum (fall-39) och dess användning
US5654273A (en) 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
EP0935965A4 (en) 1996-04-23 2002-01-23 Toray Industries SUBSTANCE AGAINST PYLORI
SE515982C2 (sv) * 1998-03-06 2001-11-05 Lipocore Holding Ab Användning av en olja-i-vatten emulsion som bärare för framställning av en topikal kräm eller lotion
US5925534A (en) * 1998-06-08 1999-07-20 Wako Pure Chemical Industries, Ltd. Method for measuring LDL-cholesterol
WO2000057895A1 (en) 1999-03-26 2000-10-05 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
US7335355B2 (en) 2000-07-17 2008-02-26 Hansa Medical Ab Antimicrobial agent
AU2000265672A1 (en) 2000-07-27 2002-02-13 Apogene Gmbh And Co. Kg Somatic cloning gene transfer for the production of recombinant proteins, cells and organs
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
US20030022829A1 (en) * 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
GB0223655D0 (en) * 2002-10-10 2002-11-20 Mabtech Ab Method of diagnosis
NZ540506A (en) 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition

Also Published As

Publication number Publication date
CA2513598C (en) 2015-04-21
US9125875B2 (en) 2015-09-08
US8936807B2 (en) 2015-01-20
SI1589987T1 (sl) 2014-07-31
CY1115142T1 (el) 2016-12-14
US20150094256A1 (en) 2015-04-02
SE0300207D0 (sv) 2003-01-29
CN1744913B (zh) 2010-05-26
EP1589987A1 (en) 2005-11-02
HK1217661A1 (zh) 2017-01-20
PT1589987E (pt) 2014-05-28
US20070149448A1 (en) 2007-06-28
JP4750690B2 (ja) 2011-08-17
ZA200505830B (en) 2006-04-26
CN101838326A (zh) 2010-09-22
US8012933B2 (en) 2011-09-06
EP1589987B1 (en) 2014-04-23
CN1744913A (zh) 2006-03-08
ES2467090T3 (es) 2014-06-11
CN105079784A (zh) 2015-11-25
US8506994B2 (en) 2013-08-13
US7452864B2 (en) 2008-11-18
US20110293707A1 (en) 2011-12-01
US20090088382A1 (en) 2009-04-02
WO2004067025A1 (en) 2004-08-12
JP2006518375A (ja) 2006-08-10
CA2513598A1 (en) 2004-08-12
US20130287839A1 (en) 2013-10-31
CN105079784B (zh) 2018-05-18

Similar Documents

Publication Publication Date Title
DK1589987T3 (da) Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1703909T3 (da) 1-benzoyl-piperazinderivater som glycinoptagelsesinhibitorer til behandling af psykoser
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1755661T3 (da) Gelsolin til anvendelse til behandling af infektioner
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DK1865976T3 (da) Anvendelse af natriuretiske peptider til behandling af hjertesvigt
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
DK1959981T3 (da) Anti-connexin 43 forbindelser til behandling af kroniske sår
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
NO20055820D0 (no) Peptider til anvendelse ved behandling av overvekt
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1803456T5 (da) Farmaceutiske sammensætninger omfattende L-733060 til anvendelse ved behandling af cancertumorer
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1694342T3 (da) Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
DE60220914D1 (de) Aminoacetonitril-verbindungen zur bekämpfung von endoparasiten
DE602004013557D1 (de) FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme